Subscription Agency
Exploring and Distributing Knowledge Globally

Journal of Pharma Innovations
Volume 5 Issue 1, 2025

Review Article: Formulation and Optimization of In situ Ophthalmic Gel: A Novel Approach for Enhanced Ocular Drug Delivery

Rahul Kamble*, Dr. Amol U. Gayke, Vikas S. Shinde, Mayur Shinde, Prasad Mokal, Gaurav Gavit, Tejaswini Pawar
Department of Pharmaceutics, SND College of Pharmacy Babhulgaon Yeola, Nashik-423401 (Maharashtra) India

Corresponding author
Email id- kamblerahul1992001@gmail.com

ABSTRACT

In situ gels represent an innovative and promising approach for enhancing ocular drug delivery, addressing the limitations of conventional eye drops, such as rapid drainage and poor bioavailability. This review explores the formulation and optimization of in situ ophthalmic gels, with a focus on Brimonidine Tartrate, a widely used α2-adrenergic agonist for glaucoma treatment. These gels are designed to transition from a liquid to a gel form upon contact with ocular tissues, providing prolonged retention time, controlled release, and improved bioavailability. The review discusses various polymer systems, including temperature-sensitive, pH-sensitive, and ion-sensitive gels, and highlights their role in enhancing ocular retention and drug release. Additionally, the challenges and strategies for optimizing in situ gels for ophthalmic applications are examined. The potential advantages of in situ gel formulations, including reduced dosing frequency and improved patient compliance, are emphasized, particularly for the delivery of Brimonidine Tartrate. In conclusion, in situ gels offer significant promise as an advanced drug delivery system for ocular therapy, with the potential to improve the management of glaucoma and other ocular conditions.

Keywords- *In situ gel**,** Ocular drug delivery**,** Brimonidine Tartrate**,** Ophthalmic formulations**,** Drug release.*

INTRODUCTION

Ocular drug delivery remains a major challenge in the treatment of various eye disorders due to the unique anatomy and physiology of the eye. Traditional eye drops face significant drawbacks, such as rapid drainage, low bioavailability, and frequent dosing, which often result in suboptimal therapeutic outcomes. In response to these limitations, in situ gel systems have emerged as an innovative approach to enhance the efficacy of ocular drug delivery.[1] These gels are liquid at the time of administration and undergo gelation at the site of application, triggered by physiological stimuli such as pH, temperature, or ionic strength. This review focuses on the formulation, optimization, and potential applications of in situ ophthalmic gels, with a particular emphasis on the delivery of Brimonidine Tartrate, an α2-adrenergic agonist used in the management of glaucoma. The eye is a complex and unique part of the human organs that has been considered as the window to the human soul. Broadly, the human eye is divided into two segments that are anterior and posterior segments.[2] The specific disease conditions of the eye are associated with each of these broad segments. For instance, conjunctivitis, glaucoma, blepharitis, and cataract are some of the diseases that

affect the anterior segment of the eye, while diabetic retinopathy and age-related macular degeneration are known to affect the posterior segment.[3]



Fig. 1 – In-situ forming gels process. The formulation is liquid when instilled into the eye which undergoes gel formation rapidly in the cul-de-sac of the eye in response to environmental changes such as pH, temperature and ion; finally release the drug slowly under physiological conditions.

In-situ gelling system

Ophthalmic in-situ gelling is comprising of environmentally sensitive polymers that will be altered structurally with the small changes in specific conditions like pH, temperature and ionic strength in the environment.[4] In-situ forming gels are liquids during instillation into the eye and then undergoes rapid gelation in the cul-de-sac of the eye to form viscoelastic gels in response to environmental changes (Fig. 1); lastly release the drug slowly under physiological conditions[5]. Consequently, the residence time of the gel formed in-situ will be extended and the drug is released in a sustained manner which leads to enhanced bioavailability, minimized systemic absorption and reduced frequent dosing regimen resulting to improved patient compliance[6]. Furthermore, some other potential advantages such as simple manufacturing process, ease of administration, and deliverance of accurate dose have been exhibited by in-situ gelling systems[7].

Mechanisms of gelling system

In-situ gel formation may be achieved by a number of mechanisms including temperature, pH- and ion-activated systems. Temperature triggered in-situ gel system which utilizes the temperature sensitive polymers that exist as a liquid form below its low critical solution temperature (LCST) and undergoes gelation when the environmental temperature reaches or is above the LCST[8]. The pH induced in-situ gel contains polymers which possess acidic or alkaline functional groups within the chain molecule and undergoes a sol-gel phase transition on change from a low pH to high pH environment[9]. Ion-activated systems are also known as osmotically triggered in-situ gel systems wherein the polymer undergoes a sol-gel transition due to changes of ionic concentration, which is typically triggered by mono or divalent cations in tear fluid particularly Na+, Mg2+and Ca2+[10]. In addition, sol-gel phase transition has known to be induced by enzymatic cross linking and photon polymerization[11]. However, the pH, temperature, and ion-induced in-situ gel are the most extensively studied approaches of in-situ gel, and the concern of this review.

Clinical application of in-situ gelling

To date, some of in-situ gel formulations have been commercially available for ocular drug delivery. For instance, Timoptic-XE®, containing timolol maleate (0.25% and 0.5%) in gellan gum has been available on market since 1994, which is applied topically on the eye to treat glaucoma. Furthermore, some of the patents on in-situ gel for ocular delivery system have been issued in the last decades, and are being summarized.[12]

Challenges in Ocular Drug Delivery[13-15]

Ocular drug delivery is a highly specialized field that requires overcoming several biological barriers, including:

a) **Tear drainage:** Tears rapidly flush out drug formulations, reducing their residence time on the corneal surface.
b) **Blood-aqueous barrier:** Limits the absorption of drugs into the systemic circulation.
c) **Corneal barrier:** Restricts drug permeation through the cornea, especially for hydrophilic molecules.

These challenges contribute to the low bioavailability of conventional ocular drug delivery systems, typically below 5%, necessitating frequent administration to achieve therapeutic concentrations.

In Situ Gel Systems for Ocular Delivery[16-18]

In situ gels are promising candidates for ocular drug delivery due to their ability to form a gel at the site of administration. This transformation improves the residence time of the drug, ensuring sustained drug release and reducing the frequency of dosing.

Mechanism of Gelation[19-21]

In situ gels are designed to undergo a sol-to-gel transition in response to various physiological stimuli:

a) **Temperature-Sensitive Gels:** These gels undergo gelation upon reaching body temperature (e.g., Poloxamers).
b) **pH-Sensitive Gels:** Gelation occurs when the pH of the formulation changes (e.g., Carbopol).
c) **Ion-Sensitive Gels:** Gelation is induced by changes in ionic concentration (e.g., Gellan gum).

Advantages of In Situ Gels[22-23]

- **Prolonged Retention Time:** By forming a gel at the ocular surface, in situ gels adhere better and stay longer, reducing tear drainage and improving drug absorption.
- **Reduced Systemic Absorption:** By maintaining the drug at the site of application, in situ gels minimize the potential for systemic side effects.
- **Improved Patient Compliance:** The need for less frequent dosing and the ease of administration as a liquid makes these formulations more patient-friendly.
- **Sustained and Controlled Release:** In situ gels can provide a steady release of drugs over an extended period, improving the therapeutic outcome.

Formulation Strategies for In Situ Ophthalmic Gels[23-24]

The formulation of in situ ophthalmic gels involves careful selection of polymers and excipients to achieve the desired gelation behavior, drug release profile, and ocular compatibility. Key considerations include:

- **Polymer Selection:**

a) **Poloxamers:** Thermosensitive gels that undergo gelation at body temperature and are commonly used for ocular drug delivery.
b) **Carbopol:** pH-sensitive gel-forming polymer that offers controlled release by changing viscosity in response to pH variations.
c) **Gellan Gum:** Ion-sensitive polymer that gels in the presence of multivalent cations.
d) **Chitosan:** A biocompatible and biodegradable polysaccharide with mucoadhesive properties, which enhances ocular retention.

- **Excipients:**
  a) **Buffers and pH adjusters** are used to maintain the stability and gelation properties of the formulation.
  b) **Isotonic agents** ensure ocular compatibility, preventing irritation or damage to the eye.
  c) **Preservatives** may be added to prevent microbial contamination.

Optimization of In Situ Gel Formulations[25-26]

Formulation optimization plays a crucial role in ensuring the efficacy and stability of in situ gels. The optimization process generally focuses on:

- **Viscosity:** The formulation must be fluid enough to be administered as a liquid and viscous enough to form a gel upon contact with the ocular surface.
- **Gelation Temperature/ pH:** The gelation temperature or pH must align with physiological conditions (e.g., body temperature for thermosensitive gels or pH ~7.4 for ophthalmic formulations).
- **Drug Release Profile:** A sustained, controlled release of the drug is essential for ensuring the therapeutic effect over time. The release profile can be adjusted by varying polymer concentration, molecular weight, and crosslinking.
- **Ocular Retention:** The formulation should provide adequate retention time on the ocular surface, which can be influenced by polymer type, concentration, and the presence of mucoadhesive agents like chitosan.

Brimonidine Tartrate in Ophthalmic In Situ Gels

Brimonidine Tartrate is widely used in the treatment of glaucoma and ocular hypertension. However, its conventional eye drop formulations suffer from poor ocular bioavailability and frequent dosing. In situ gels offer a promising solution by increasing ocular retention, improving drug absorption, and providing sustained IOP reduction.[27]

Benefits of In Situ Gels for Brimonidine Tartrate

a) **Enhanced Retention:** The gelation at the ocular surface can significantly prolong Brimonidine Tartrate's contact time, reducing the need for frequent application.
b) **Sustained Release:** Controlled release formulations can provide prolonged IOP-lowering effects, reducing the need for multiple daily doses.
c) **Improved Bioavailability:** Increased retention time at the target site leads to improved drug absorption and higher bioavailability.[28]

Formulation of Brimonidine Tartrate In Situ Gels[29-30]

Formulation strategies for Brimonidine Tartrate in situ gels include:

a) **Thermosensitive Polymers:** Using Poloxamer-based systems to deliver Brimonidine Tartrate with prolonged action and reduced dosing frequency.

b) **pH-Sensitive Polymers:** Carbopol-based systems that gel upon contact with the slightly alkaline pH of the eye.
c) **Mucoadhesive Polymers:** Chitosan or HPMC can be used to enhance the retention time of the gel at the ocular surface.

CONCLUSION

In situ ophthalmic gels represent a promising approach to enhance ocular drug delivery, overcoming the limitations of traditional formulations. With the ability to provide sustained release, increased retention time, and reduced systemic absorption, these systems have the potential to improve the management of ocular diseases like glaucoma. The formulation and optimization of Brimonidine Tartrate in situ gels is a step toward more effective, patient-friendly ocular drug delivery systems, contributing to improved therapeutic outcomes and enhanced patient compliance.

REFERENCES

1) Yumei Wu , Yuanyuan Liua, Xinyue Li, Dereje Kebebe, Bing Zhang, Jing Rena, Jun Luf , Jiawei Li, Shouying Dud, Zhidong Liua,b, Research progress of in-situ gelling ophthalmic drug delivery system, Asian Journal of Pharmaceutical Sciences 14 (2019) 1–15.
2) Addo E, Bamiro OA, Siwale R. Anatomy of the eye and common diseases affecting the eye. In: Addo RT, editor. Ocular drug delivery: Advances, challenges and applications.; 2016. p. 11–25.
3) Joseph RR, Venkatraman SS. Drug delivery to the eye: what benefits do nanocarriers offer. Nanomedicine (Lond) 2017;12(6):683–702.
4) Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug Dev Ind Pharm 2013;39(11):1599–617.
5) Khan N, Aqil M, Imam SS, Ali A. Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization. Pharm Dev Technol 2015;20(6):662–9.
6) Li J, Zhao H, Okeke CI, et al. Comparison of systemic absorption between ofloxacin ophthalmic in situ gels and ofloxacin conventional ophthalmic solutions administration to rabbit eyes by HPLC-MS/MS. Int J Pharm 2013;450(1-2):104–13.
7) Devasani SR, Dev A, Rathod S, Deshmukh G. An overview of in situ gelling systems. Pharmaceut Biolog Evaluat 2016;3(1):60–9.
8) Cao Y, Zhang C, Shen W, Cheng Z, Yu LL, Ping Q. Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Control Release 2007;120(3):186–94.
9) Sheshala R, Kok YY, Ng JM, Thakur RR, Dua K. In situ gelling ophthalmic drug delivery system: an overview and its applications. Recent Pat Drug Deliv Formul 2015;9(3):237–48.
10) Laddha UD, Mahajan HS. An insight to ocular in situ gelling systems. Int J Adv Pharmaceut 2017;06(02):31–40.
11) Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release 2002;83(1):65–74.
12) Fernandez-Ferreiro A, Fernandez Bargiela N, Varela MS, et al. Cyclodextrin-polysaccharide-based, in situ-gelled system for ocular antifungal delivery. Beilstein J Org Chem 2014;10:2903–11.

13) Reed K, Li A, Wilson B, Assamoi T. Enhancement of ocular in situ gelling properties of low acyl gellan gum by use of ion exchange. J Ocul Pharmacol Ther 2016;32(9):574–82.
14) Champalal KD, Sushilkumar SP. Current status of ophthalmic in-situ forming hydrogel. Int J Pharma Bio Sci 2012;3(3):P372–88.
15) Mishra DN, Gilhotra RM. Design and characterization of bioadhesive in-situ gelling ocular inserts of Gatifloxacin sesquihydrate. DARU: J Pharmaceut Sci 2008;16(1):1–8.
16) Nirmal HB, Bakliwal SR, Pawar SP. In-situ gel: new trends in controlled and sustained drug delivery system. Int J PharmTech Res 2010;2(2):1398–408.
17) Vijaya C, Goud KS. Ion-activated in situ gelling ophthalmic delivery systems of Azithromycin. Indian J of Pharm Sci 2011;73(6):615–20.
18) Zhu L, Ao J, Li P. A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: in vitro and in vivo evaluation. Drug Des Devel Ther 2015;9:3943–9.
19) Kesarla R, Tank T, Vora PA, Shah T, Parmar S, Omri A. Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel. Drug Deliv 2016;23(7):2363–70.
20) Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int J Pharm 2013;443(1-2):293–305.
21) Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006;315(1-2):12–17.
22) Liu Z, Yang XG, Li X, Pan W, Li J. Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis. Drug Dev Ind Pharm 2007;33(12):1327–31.
23) Morsi N, Ibrahim M, Refai H, El Sorogy H. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur J Pharm Sci 2017;104:302–14.
24) Rupenthal ID, Alany RG, Green CR. Ion-activated in situ gelling systems for antisense oligodeoxynucleotide delivery to the ocular surface. Mol Pharm 2011;8(6):2282–90.
25) Yu S, Zhang X, Tan G, et al. A novel pH-induced thermosensitive hydrogel composed of carboxymethyl chitosan and poloxamer cross-linked by glutaraldehyde for ophthalmic drug delivery. Carbohydr Polym 2017;155:208–17.
26) Davaran S, Lotfipour F, Sedghipour N, Sedghipour MR, Alimohammadi S, Salehi R. Preparation and in vivo evaluation of in situ gel system as dual thermo-/pH-responsive nanocarriers for sustained ocular drug delivery. J Microencapsul 2015;32(5):511–19.
27) Xu H, Liu Y, Jin L, Chen X, Chen X, Wang Q, Tang Z. Preparation and Characterization of Ion-Sensitive Brimonidine Tartrate In Situ Gel for Ocular Delivery. Pharmaceuticals (Basel). 2023 Jan 8;16(1):90.
28) Cai J., Li L., Song Y., Xu L., Mao Y., Wang H. Neuroprotective Effect of Brimonidine against Facial Nerve Crush Injury in Rats via Suppressing GFAP/PAF Activation and Neuroinflammation. ORL J. Otorhinolaryngol. Relat. Spec. 2021;83:449–456.
29) Chiang B., Kim Y.C., Doty A.C., Grossniklaus H.E., Schwendeman S.P., Prausnitz M.R. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma. J. Control. Release. 2016;228:48–57.
30) Sun J., Zhou Z. A novel ocular delivery of brinzolamide based on gellan gum: In vitro and in vivo evaluation. Drug Des. Dev. Ther. 2018;12:383–389.